SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-078131
Filing Date
2018-03-12
Accepted
2018-03-12 06:06:06
Documents
3
Period of Report
2018-03-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d548491d8k.htm 8-K 29653
2 EX-10.1 d548491dex101.htm EX-10.1 548673
3 EX-99.1 d548491dex991.htm EX-99.1 34995
  Complete submission text file 0001193125-18-078131.txt   614863
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33415 | Film No.: 18681886
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences